A predictive model of UV-A-riboflavin crosslinking treatment on porcine corneas

The crosslinking technique (CXL) is an effective low-risk therapeutic treatment of keratoconus and other ectatic disorders of the human cornea. The effect of corneal CXL is to increase the stiffness of the stroma to prevent the progression of the cornea distortion. Several clinical and experimental...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Proceedings of the Royal Society. A, Mathematical, physical, and engineering sciences Mathematical, physical, and engineering sciences, 2023-11, Vol.479 (2279)
Hauptverfasser: Bonfanti, Alessandra, Pandolfi, Anna
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:The crosslinking technique (CXL) is an effective low-risk therapeutic treatment of keratoconus and other ectatic disorders of the human cornea. The effect of corneal CXL is to increase the stiffness of the stroma to prevent the progression of the cornea distortion. Several clinical and experimental studies have shown that the stiffening effects predominantly localize on the anterior portion of the stroma and that the in-depth stiffening distribution is highly dependent on the duration of treatment. Yet, how the stiffening effects distribute through the cornea thickness as a function of the treatment duration is an open question. Here, we propose an analytical model of the stiffening profile due to CXL treatment as a function of the irradiation time. We consider linear and nonlinear variations of the crosslinking effects across the thickness and implement them into a finite element model of the porcine cornea. We present a time-dependent in-depth stiffening profile that allows us to predict the post-operative cornea response to physiological intraocular pressure for different irradiation times. We anticipate that this predictive model will support the development of patient specific three-dimensional models that will allow clinicians to design customized CXL treatment, thus enhancing treatment outcomes.
ISSN:1364-5021
1471-2946
DOI:10.1098/rspa.2023.0323